Discover trends, market shifts, and competitive outlooks for the sustained release excipients industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Sustained Release Excipients Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, the market size for sustained release excipients has considerably expanded. It is projected to escalate from $1.4 billion in 2024 to $1.53 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%. This growth during the historic period can be ascribed to a surge in demand for regulated drug release, the prevalence of chronic diseases, patient adherence and convenience, innovative measures in the pharmaceutical industry, and regulatory backing for extended-release formulations.

The market size of sustained release excipients is projected to experience a significant expansion in the coming years. The expected value is around “$2.13 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%. The anticipated growth during the forecast period is due to factors such as the increasing elderly population, an emphasis on personalized medication, issues with patient adherence, the emergence of complex drug formulations, advancements in disease management, and the expansion of global healthcare. Major emerging trends during this period include a focus on patient-centric drug delivery, partnerships for formulation development, adherence to regulatory compliance and safety, worldwide expansion of drug formulation technologies, and the impact of biopharmaceuticals.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What External and Internal Drivers Are Contributing to the Growth of theSustained Release Excipients Market?

The growth of the sustained-release excipients market is forecasted to be driven by the rising prevalence of both chronic and acute illnesses. These two categories are used to define illnesses based on their progression and duration. Chronic illnesses are those medical conditions enduring over a lengthy period, usually more than three months. On the other hand, acute illnesses present rapidly developing, often intense symptoms, but are short in duration, lasting from hours to days or weeks. Sustained-release excipients, used to manufacture drugs for both chronic and acute illnesses, enhance patient compliance, maintain steady drug levels, mitigate side effects and improve disease management. These benefits contribute to a boost in the sales of sustained-release excipients. As per the World Health Organization (WHO) in September 2022, 17.9 million annual NCD deaths were due to cardiovascular diseases, followed by chronic respiratory illnesses (4.1 million), diabetes related fatalities including renal disease (2.0 million), and cancer (9.3 million). Moreover, in August 2022, a report by the American College of Cardiology projected a nationwide increase in all four principal cardiovascular risk factors from 2025 to 2060. Diabetes is predicted to see the most significant rise – a 39.3% increase to 55 million, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Substantial rises are also expected in cardiovascular disease rates for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) trailings closely. Therefore, the escalating prevalence of chronic and acute health issues propels the growth of the sustained-release excipients market.

What Segment Types Define the Sustained Release Excipients Market Structure?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Sustained Release Excipients Market?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Sustained Release Excipients Market?

Product development remains a dominating trend within the sustained release excipients market, with leading corporations innovating their offerings to solidify their market presence. For instance, Nutriventia Limited, a pharmaceutical organization hailing from India, introduced Prolanza, a sustained-release variant of the ashwagandha ingredient (Withania somnifera) in September 2022. This avant-garde root-only extract of Ashwagandha extends constant support in lowering stress. Thanks to its unique release system, Prolanza delivers its healing benefits throughout an extended timeframe with a single daily dosage. As compared to a control component, Prolanza showed enhanced relative intake, better bioavailability, and an extended elimination half-life, proving its sustained-release nature. The health benefits of Prolanza are amplified due to the primary usage of ashwagandha, which is to adapt and reduce stress responses. Made from all-natural herbs and clinically verified to deliver results, the therapeutic effects of Prolanza can be experienced for a longer duration.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

What Is the Definition of the Sustained Release Excipients Market?

Sustained-release excipients refer to pharmaceutical ingredients or additives used in the formulation of drug delivery systems designed to achieve controlled or sustained release of active pharmaceutical ingredients (APIs) over an extended period of time. These excipients play a crucial role in controlling the release rate and duration of drug action, thereby optimizing therapeutic efficacy and patient compliance.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10822

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model